MammaPrint South Africa

  • Home
  • MammaPrint South Africa

MammaPrint South Africa We provide a Precision Medicine Solution for women with early stage breast cancer. 🎀

In South Africa, the 150-gene MammaPrint & BluePrint assay is not routinely requested by oncologists for patients with t...
21/06/2025

In South Africa, the 150-gene MammaPrint & BluePrint assay is not routinely requested by oncologists for patients with triple-negative breast cancer. We now increasingly see the value for a subset of breast cancer patients due to their unique biology. Thank you Lwando Mampunye for highlighting the value of the first-tier ParaDNA point-of-care BRCA1/2 Research Assay to integrate germline and tumour genetics!

New data presented at from Agendia’s Study is improving our understanding of breast cancer care. From real-world insights to genomic advancements, our latest presented findings explore:

🔬 Genomic signatures & survival outcomes by race in TNBC: https://ow.ly/bTqj50W7gKj
👩🏾‍🤝‍👩🏼 Equitable clinical outcomes across races with MammaPrint: https://ow.ly/85fp50W7gKi
🎯 Precision treatment planning for patients 70+: https://ow.ly/z3Hs50W7gKn
🧬 Molecular predictors of response in neoadjuvant therapy: https://ow.ly/z7v950W7gKg

Would you like to discuss the data in more depth? Schedule a meeting with our Medical Team to review the data: https://ow.ly/RMFZ50W7gKk

27/01/2025

Olivia Munn announced she was diagnosed with this form of cancer in 2023.

The MammaPrint test became available for routine use in South Africa after FDA approval in 2007, followed by the BluePri...
28/12/2024

The MammaPrint test became available for routine use in South Africa after FDA approval in 2007, followed by the BluePrint test from 2012. Both tests are performed on formalin-fixed paraffin embedded tumour biopsies and reimbused as part of oncology benefits by many medical schemes.

Agendia corporate video. Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

South African patients with the luminal breast cancer subtype are not routinely referred for BRCA1/2 testing as is the c...
27/12/2024

South African patients with the luminal breast cancer subtype are not routinely referred for BRCA1/2 testing as is the case for triple-negative tumours. In 2020, a pioneering study by Lwando Mampunye (https://digitalknowledge.cput.ac.za/handle/11189/8923) and co-investigators highlighted the extremely high risk for both a second primary cancer and breast cancer metastasis in BRCA carriers with a high-risk MammaPrint 70-gene profile. (DOI: 10.3389/fonc.2021.619817).

In October 2024, the South African Medical Research Council awarded Gknowmix with a major research grant to help reduce this "double risk". For more information please email Prof Maritha Kotze (maritha@sun.ac.za/maritha.kotze@gmail.com).

To better understand where the MammaPrint test fits into breast cancer risk management, we introduce you to the Open p...
27/12/2024

To better understand where the MammaPrint test fits into breast cancer risk management, we introduce you to the Open project led by Dr Nicole van der Merwe :

The Open Genome Project is an initiative of Gknowmix, a spin-out company of the South African Medical Research Council. We developed an adaptable report temp...

Address


Website

http://gknowmix.app/

Alerts

Be the first to know and let us send you an email when MammaPrint South Africa posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MammaPrint South Africa:

Shortcuts

  • Address
  • Alerts
  • Contact The Practice

  • Want your practice to be the top-listed Clinic?

Share